# A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia

> **NCT05883956** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Otsuka Australia Pharmaceutical Pty Ltd** · enrollment: 13 (actual)

## Conditions studied

- Myelodysplastic Syndromes
- Leukemia, Myeloid, Acute
- Leukemia, Myelomonocytic, Chronic
- Patient Preference

## Interventions

- **DRUG:** Subcutaneous azacitidine
- **DRUG:** Oral decitabine/cedazuridine

## Key facts

- **NCT ID:** NCT05883956
- **Lead sponsor:** Otsuka Australia Pharmaceutical Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-20
- **Primary completion:** 2024-12-06
- **Final completion:** 2025-05
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2025-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05883956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05883956, "A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05883956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*